771 reports of this reaction
3.5% of all GRANISETRON HYDROCHLORIDE reports
#3 most reported adverse reaction
DIARRHOEA is the #3 most commonly reported adverse reaction for GRANISETRON HYDROCHLORIDE, manufactured by Fresenius Kabi USA, LLC. There are 771 FDA adverse event reports linking GRANISETRON HYDROCHLORIDE to DIARRHOEA. This represents approximately 3.5% of all 22,079 adverse event reports for this drug.
Patients taking GRANISETRON HYDROCHLORIDE who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DIARRHOEA is moderately reported among GRANISETRON HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to diarrhoea, the following adverse reactions have been reported for GRANISETRON HYDROCHLORIDE:
The following drugs have also been linked to diarrhoea in FDA adverse event reports:
DIARRHOEA has been reported as an adverse event in 771 FDA reports for GRANISETRON HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DIARRHOEA accounts for approximately 3.5% of all adverse event reports for GRANISETRON HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience diarrhoea while taking GRANISETRON HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.